Study of Malignant Portal Vein Thrombosis in Hepatocellular Carcinoma and its Relation with other Prognostic Factors
Beltagi M, Ibrahim EH, Rizk MM, Hassona
EM, Elaassar OS, Elhasafi AM
Correspondence Address :
Beltagi M, Ibrahim
Department of Hepatology
Faculty of Medicine
Received on: December 27, 2018, Accepted on: January 14, 2019, Published on: January 28, 2019
Citation: Beltagi M Ibrahim EH, Rizk MM, Hassona EM, Elaassar OS, Elhasafi AM (2019). Study of Malignant Portal Vein Thrombosis in
Hepatocellular Carcinoma and Its Relation with other Prognostic Factors.
Copyright: 2019 Beltagi M Ibrahim EH et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Hepatocellular carcinoma is a leading cause of death from cancer worldwide. Survival and prognosis of patients depends on tumor extension and liver function, but yet there is no consensual prognostic model.
Aim of the work: The aim of this work is to study malignant portal vein thrombosis in patients with hepatocellular carcinoma. Also, to evaluate the relation of the presence of portal vein thrombosis to other prognostic factors such as tumor burden (number, size, and lobular distribution of the tumor), alpha fetoprotein level, PIVKA II, the Child-Pugh score of liver cirrhosis, and extra hepatic metastasis.
Subjects: The study was carried out on 50 human participants with hepatocellular carcinoma. Patients were further classified into two groups: Group A: 25 Patient with malignant portal vein thrombosis, Group B: 25 Patient without malignant portal vein thrombosis.
Results: HCV marker was higher in both groups with 18(72%) and 20(80%) respectively. There was statistical significant difference between the two studied groups regarding ALP, Total bilirubin and direct bilirubin. There was no statistical significant difference between the two studied groups regarding Child-Pugh classifications. There was statistical significant difference between the two studied groups regarding AFP while, there was no statistical significant difference regarding to S.PIVKA. There was statistical significant difference between the two studied groups regarding the tumor size. There was statistical significant difference between the two studied groups regarding vascular invasion, Nodular invasion and Extrahepatic metastasis.
Conclusion: This study reinforces the importance of baseline liver function (Child-Pugh classification and MELD score) in the survival of patients with HCC, although staging systems allowed the stratification of patients in different prognostic groups. Ascites, bilirubin and PVT were independent predictors of prognosis and survival.